Opthea Ltd Appoints Sujal Shah to Board of Directors

Ticker: OPTEY · Form: 6-K · Filed: Apr 4, 2024 · CIK: 1815620

Sentiment: neutral

Topics: board-appointment, management

TL;DR

Opthea adds pharma vet Sujal Shah to its board, signaling potential strategic shifts.

AI Summary

Opthea Limited announced on April 4, 2024, the appointment of Sujal Shah as a new member of its Board of Directors. Shah brings extensive experience in the biopharmaceutical industry, having previously served as CEO of Denali Therapeutics. This appointment is effective immediately.

Why It Matters

The addition of Sujal Shah, a seasoned biopharmaceutical executive, to Opthea's board could bring valuable strategic guidance and industry connections, potentially impacting the company's future development and commercialization efforts.

Risk Assessment

Risk Level: low — This filing is a routine announcement of a board appointment and does not contain significant financial or operational news that would immediately impact the company's risk profile.

Key Players & Entities

FAQ

Who is Sujal Shah and what is his relevant experience?

Sujal Shah has been appointed to Opthea's Board of Directors. He previously served as the CEO of Denali Therapeutics and has extensive experience in the biopharmaceutical industry.

When was this appointment announced?

The announcement was made on April 4, 2024, as indicated by the filing date.

What is the significance of this filing?

This is a Form 6-K filing, reporting the appointment of a new director to the company's Board of Directors.

What is Opthea Limited's primary business?

Opthea Limited is in the business of Biological Products (No Diagnostic Substances), as indicated by its Standard Industrial Classification code [2836].

Where is Opthea Limited headquartered?

Opthea Limited is headquartered in South Yarra, Victoria, Australia.

Filing Stats: 150 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2024-04-03 17:38:05

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. OPTHEA LIMITED (Registrant) By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 04/04/2024

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing